Skip to main content
NCBI home page
Heart logoLink to Heart
. 1999 Nov;82(5):584–588. doi: 10.1136/hrt.82.5.584

Non-adherence with ACE inhibitor treatment is common in heart failure and can be detected by routine serum ACE activity assays

A Struthers 1, G Anderson 1, R MacFadyen 1, C Fraser 1, T MacDonald 1
PMCID: PMC1760770  PMID: 10525514

Abstract

OBJECTIVE—To assess whether serum angiotensin converting enzyme (ACE) activity during routine clinical practice accurately reflects patient adherence to ACE inhibitor treatment for chronic heart failure (CHF).
DESIGN—Retrospective assessment of ACE inhibitor adherence and serum ACE activity measurements.
SETTING—Teaching hospital outpatient department
PATIENTS AND INTERVENTIONS—During 1994-95, serum ACE was measured in 73 CHF patients who were routinely attending the heart failure clinic at Ninewells Hospital. At the same time, the medicines monitoring unit collected data on whether and when prescriptions for ACE inhibitors were redeemed at community pharmacies, which enabled each patient's adherence over a prolonged period to be assessed.
MAIN OUTCOME MEASURES—Routine collected serum ACE measurements were correlated with measured adherence with ACE inhibitor treatment.
RESULTS—In total, 18% of CHF patients appeared to exhibit < 70% adherence with their ACE inhibitor treatment with 34% exhibiting less than 85% adherence and 58% exhibiting < 100% adherence. A serum ACE activity of > 12 u/l gave 91% positive predictive accuracy that the patient was < 100% adherent with their ACE inhibitor treatment. At the other extreme, a serum ACE < 6.5 u/l gave 81% positive predictive accuracy that the patient was > 85% adherent with ACE inhibitor treatment.
CONCLUSIONS—Non-adherence with ACE inhibitor treatment was found to be common in patients with CHF. The simple, inexpensive test of serum ACE activity can be used in CHF patients to identify many, although not all, non-adherent patients so that adherence enhancing strategies can be targeted towards them. Further work is clearly required to explore the precise clinical use of this promising test.


Keywords: angiotensin converting enzyme inhibitors; heart failure; compliance

Full Text

The Full Text of this article is available as a PDF (92.9 KB).

Figure 1  .

Figure 1  

Open in a new tab

Overall level of adherence with ACE inhibitor treatment in CHF patients (two high ones omitted for clarity).

Figure 2  .

Figure 2  

Open in a new tab

Relation between serum ACE activity measurements and adherence with ACE inhibitor treatment in CHF patients. Linear correlation r = −0.30, p = 0.011, although the relation is really curvilinear.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Azizi M., Ezan E., Nicolet L., Grognet J. M., Ménard J. High plasma level of N-acetyl-seryl-aspartyl-lysyl-proline: a new marker of chronic angiotensin-converting enzyme inhibition. Hypertension. 1997 Nov;30(5):1015–1019. doi: 10.1161/01.hyp.30.5.1015. [DOI] [PubMed] [Google Scholar]
  2. Biollaz J., Schelling J. L., Jacot Des Combes B., Brunner D. B., Desponds G., Brunner H. R., Ulm E. H., Hichens M., Gomez H. J. Enalapril maleate and a lysine analogue (MK-521) in normal volunteers; relationship between plasma drug levels and the renin angiotensin system. Br J Clin Pharmacol. 1982 Sep;14(3):363–368. doi: 10.1111/j.1365-2125.1982.tb01992.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Corlett A. J. Aids to compliance with medication. BMJ. 1996 Oct 12;313(7062):926–929. doi: 10.1136/bmj.313.7062.926. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Davidson N. C., Coutie W. J., Webb D. J., Struthers A. D. Hormonal and renal differences between low dose and high dose angiotensin converting enzyme inhibitor treatment in patients with chronic heart failure. Heart. 1996 Jun;75(6):576–581. [PMC free article] [PubMed] [Google Scholar]
  5. Ghali J. K., Kadakia S., Cooper R., Ferlinz J. Precipitating factors leading to decompensation of heart failure. Traits among urban blacks. Arch Intern Med. 1988 Sep;148(9):2013–2016. [PubMed] [Google Scholar]
  6. Haynes R. B., McKibbon K. A., Kanani R. Systematic review of randomised trials of interventions to assist patients to follow prescriptions for medications. Lancet. 1996 Aug 10;348(9024):383–386. doi: 10.1016/s0140-6736(96)01073-2. [DOI] [PubMed] [Google Scholar]
  7. MacFadyen R. J., Struthers A. D. The practical assessment of compliance with ACE-inhibitor therapy--a novel approach. J Cardiovasc Pharmacol. 1997 Jan;29(1):119–124. doi: 10.1097/00005344-199701000-00018. [DOI] [PubMed] [Google Scholar]
  8. Monane M., Bohn R. L., Gurwitz J. H., Glynn R. J., Avorn J. Noncompliance with congestive heart failure therapy in the elderly. Arch Intern Med. 1994 Feb 28;154(4):433–437. [PubMed] [Google Scholar]
  9. Morris A. D., Boyle D. I., McMahon A. D., Greene S. A., MacDonald T. M., Newton R. W. Adherence to insulin treatment, glycaemic control, and ketoacidosis in insulin-dependent diabetes mellitus. The DARTS/MEMO Collaboration. Diabetes Audit and Research in Tayside Scotland. Medicines Monitoring Unit. Lancet. 1997 Nov 22;350(9090):1505–1510. doi: 10.1016/s0140-6736(97)06234-x. [DOI] [PubMed] [Google Scholar]
  10. Nussberger J., Brunner D., Keller I., Brunner H. R. Measurement of converting enzyme activity by antibody-trapping of generated angiotensin II. Comparison with two other methods. Am J Hypertens. 1992 Jun;5(6 Pt 1):393–398. doi: 10.1093/ajh/5.6.393. [DOI] [PubMed] [Google Scholar]
  11. Rich M. W., Beckham V., Wittenberg C., Leven C. L., Freedland K. E., Carney R. M. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med. 1995 Nov 2;333(18):1190–1195. doi: 10.1056/NEJM199511023331806. [DOI] [PubMed] [Google Scholar]
  12. Swedberg K., Eneroth P., Kjekshus J., Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation. 1990 Nov;82(5):1730–1736. doi: 10.1161/01.cir.82.5.1730. [DOI] [PubMed] [Google Scholar]
  13. Swedberg K., Held P., Kjekshus J., Rasmussen K., Rydén L., Wedel H. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II) N Engl J Med. 1992 Sep 3;327(10):678–684. doi: 10.1056/NEJM199209033271002. [DOI] [PubMed] [Google Scholar]
  14. van Veldhuisen D. J., Genth-Zotz S., Brouwer J., Boomsma F., Netzer T., Man In 'T Veld A. J., Pinto Y. M., Lie K. I., Crijns H. J. High- versus low-dose ACE inhibition in chronic heart failure: a double-blind, placebo-controlled study of imidapril. J Am Coll Cardiol. 1998 Dec;32(7):1811–1818. doi: 10.1016/s0735-1097(98)00464-1. [DOI] [PubMed] [Google Scholar]

Articles from Heart are provided here courtesy of BMJ Publishing Group

RESOURCES